ME02442B - Miševi koji ispoljavaju laki lanac hibridnog imunoglobulina sa promenljivim regionom čovjeka - Google Patents

Miševi koji ispoljavaju laki lanac hibridnog imunoglobulina sa promenljivim regionom čovjeka

Info

Publication number
ME02442B
ME02442B MEP-2016-119A MEP11916A ME02442B ME 02442 B ME02442 B ME 02442B ME P11916 A MEP11916 A ME P11916A ME 02442 B ME02442 B ME 02442B
Authority
ME
Montenegro
Prior art keywords
gene
mouse
light chain
endogenous
human
Prior art date
Application number
MEP-2016-119A
Other languages
German (de)
English (en)
French (fr)
Inventor
Lynn Macdonald
Sean Stevens
Cagan Gurer
Andrew J Murphy
Karolina A Hosiawa
Original Assignee
Regeneron Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Regeneron Pharma filed Critical Regeneron Pharma
Publication of ME02442B publication Critical patent/ME02442B/me

Links

Classifications

    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
    • A01K67/027—New or modified breeds of vertebrates
    • A01K67/0275—Genetically modified vertebrates, e.g. transgenic
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0603—Embryonic cells ; Embryoid bodies
    • C12N5/0606—Pluripotent embryonic cells, e.g. embryonic stem cells [ES]
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
    • A01K67/027—New or modified breeds of vertebrates
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
    • A01K67/027—New or modified breeds of vertebrates
    • A01K67/0275—Genetically modified vertebrates, e.g. transgenic
    • A01K67/0278—Knock-in vertebrates, e.g. humanised vertebrates
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C07K16/461—Igs containing Ig-regions, -domains or -residues form different species
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C07K16/461—Igs containing Ig-regions, -domains or -residues form different species
    • C07K16/462—Igs containing a variable region (Fv) from one specie and a constant region (Fc) from another
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/8509—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells for producing genetically modified animals, e.g. transgenic
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2207/00—Modified animals
    • A01K2207/15—Humanized animals
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/05—Animals comprising random inserted nucleic acids (transgenic)
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/05—Animals comprising random inserted nucleic acids (transgenic)
    • A01K2217/052—Animals comprising random inserted nucleic acids (transgenic) inducing gain of function
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/07—Animals genetically altered by homologous recombination
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/07—Animals genetically altered by homologous recombination
    • A01K2217/072—Animals genetically altered by homologous recombination maintaining or altering function, i.e. knock in
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/15—Animals comprising multiple alterations of the genome, by transgenesis or homologous recombination, e.g. obtained by cross-breeding
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2227/00—Animals characterised by species
    • A01K2227/10—Mammal
    • A01K2227/105—Murine
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2267/00—Animals characterised by purpose
    • A01K2267/01—Animal expressing industrially exogenous proteins
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2267/00—Animals characterised by purpose
    • A01K2267/02—Animal zootechnically ameliorated
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2267/00—Animals characterised by purpose
    • A01K2267/03—Animal model, e.g. for test or diseases
    • A01K2267/035—Animal model for multifactorial diseases
    • A01K2267/0381—Animal model for diseases of the hematopoietic system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
    • C07K2317/14—Specific host cells or culture conditions, e.g. components, pH or temperature
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/515—Complete light chain, i.e. VL + CL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/64—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising a combination of variable region and constant region components
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/8509—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells for producing genetically modified animals, e.g. transgenic
    • C12N2015/8518—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells for producing genetically modified animals, e.g. transgenic expressing industrially exogenous proteins, e.g. for pharmaceutical use, human insulin, blood factors, immunoglobulins, pseudoparticles
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2800/00—Nucleic acids vectors
    • C12N2800/30—Vector systems comprising sequences for excision in presence of a recombinase, e.g. loxP or FRT

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Immunology (AREA)
  • Environmental Sciences (AREA)
  • General Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Microbiology (AREA)
  • Biodiversity & Conservation Biology (AREA)
  • Animal Husbandry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Gynecology & Obstetrics (AREA)
  • Reproductive Health (AREA)
  • Developmental Biology & Embryology (AREA)
  • Cell Biology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Position Input By Displaying (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Electrochromic Elements, Electrophoresis, Or Variable Reflection Or Absorption Elements (AREA)
  • Medicines Containing Plant Substances (AREA)

Claims (17)

1.    Miš, koji obuhvata: a)    zamenu jednog ili više promenljivih (VH), raznovrsnih (DH) i spojnih (JH) segmenata gena teškog lanca sa jednim ili više ljudskih VH, DH, i/ili JH segmenata gena na endogenom mišjem lokusu imunoglobulina teškog lanca; i b)    endogeni λ (lambda) alel lakog lanca koji obuhvata nepreraspoređeni ljudski lambda promenljivi (hVλ) i nepreraspoređeni ljudski lambda spojni (hVλ) segment gena, gde mišji obuhvata brisanje prve Vλ-Jλ-Cλ skupine gena pomenutog endogenog mišjeg λ alela lakog lanca i zamenu, u celini ili delimično, Vλ-Jλ, segmenata gena druge skupine gena pomenutog alela sa pomenutim ljudskim Vλ, i Jλ segmentima gena koji su operativno povezani na nedirnuti mišji lambda (Cλ) gen konstantnog regiona pomenute druge Vλ-Jλ-Cλ skupine gena tako da miš ispoljava laki lanac izveden iz, hVλ. hJλ i mišji Cλ gen, i pri čemu se endogeni pojačavači Enh 2. 4, mišji lambda 3' pojačavač (Enh) i Enh 3. 1 održavaju nedirnuti u pomenutom λ alelu lakog lanca.
2.    Miš prema patentnom zahtjevu 1, pri čemu endogeni λ (lambda) alel lakog lanca obuhvata više ljudskih Vλ segmenata gena.
3.    Miš prema bilo kom od prethodnih patentnih zahtjeva, pri čemu endogeni λ (lambda) alel lakog lanca obuhvata: a)    barem 12 nepreraspoređenih ljudskih Vλ segmenata gena; ili b)    13 do 28 nepreraspoređenih ljudskih Vλ segmenata gena.
4.    Miš prema patentnom zahtjevu 3, pri čemu ljudski Vλ segmenati gena obuhvataju: a)    hVλ-1, hVλ4-3, hVλ2-8, hVλ3-8, hVλ-10, hVλ2-ll, i hVλ3-12; ili b)    hVλ2-14, hVλ3-16, hVo2-18, hVλ3-19, hVλ3-21, hVλ3-22, hVλ2-23, hVλ3-25, i hVλ3-27.
5.    Miš prema patentnom zahtevu 1, pri čemu endogeni λ (lambda) alel lakog lanca obuhvata jedan nepreraspoređeni Jλ segmenata gena koji je hJλl.
6.    Miš prema patentnom zahtjevu 1, pri čemu endogeni λ (lambda) alel lakog lanca obuhvata četiri nepreraspoređena ljudska Jλ segmenta gena.
7.    Miš prema patentnom zahtjevu 6, pri čemu četiri nepreraspoređena ljudska Jλ segmenta gena jesu Jλl, Jλ2, Jλ3, i Jλ7.
8.    Miš prema patentnom zahtjevu 1, pri čemu endogeni λ (lambda) alel lakog lanca nema endogeni Vλ segment gena.
9.    Miš prema bilo kom od patentnih zahtjeva 1 do 3, 5 i 8, pri čemu se endogeni κ(kappa) alel lakog lanca briše.
10.    Miš prema patentnom zahtjevu 1, pri čemu endogeni mišji λ alel lakog lanca obuhvata: a)    dodirunu sekvencu ljudskog λ lokusa lakog lanca koja ima raspon od Vλ3-12 do Vλ.3-1; b)    dodirunu sekvencu ljudskog λ lokusa lakog lanca koja ima raspon od Vλ3-29 do Vλ.3-1; ili sekvencu ljudskog λ lokusa lakog lanca koja ima raspon od Vλ5-52 do Vλl-40.
11.    Izolovana ćelija koja ispoljava laki lanac izveden iz hVλ, hJλ i mišjeg Cλ gena, pri čemu je ćelija iz, ili može se dobiti iz, miša prema bilo kom od prethodnih patentnih zahteva, i pri čemu ćelija obuhvata: a)    zamenu jednog ili više promenljivih (VH), raznovrsnih (DH) i spojnih (JH) segmenata    gena teškog lanca sa jednim ili više ljudskih Vh/ Dh, i Jh segmenata gena na endogenom mišjem    lokusu imunoglobulina teškog lanca; i b)    endogeni λ (lambda) alel lakog lanca koji obuhvata preraspoređeni ljudski promenljivi lambda (hVλ) i preraspoređeni ljudski spojni lambda (hJλ) segment gena, i brisanje prve Vλ-Jλ- Cλ skupine gena pomenutog endogenog mišjeg λ alela lakog lanca i zamenu, u celini ili delimično, Vλ-Jλ segmenata gena druge Vλ-Jλ-Cλ skupine gena pomenutog alela sa pomenutim ljudskim Vλ i Jλ segmentima gena koji su operativno povezani na nedirnuti mišji Cλ konstantni region gena pomenute druge Vλ-Jλ-Cλ skupine gena, i pri čemu se endogeni pojačavači Enh 2.4, mišji lambda 3' pojačavač (Enh) i Enh 3.1 održavaju nedirnuti u pomenutom λ alelu lakog lanca.
12.    Izolovana ćelija prema patentnom zahtjevu 11, pri čemu ćelija jeste B ćelija.
13.    Izolovana mišja embrionska matična (ES) ćelija obuhvata: a)    zamenu jednog ili više promenljivih (VH), raznovrsnih (DH) i spojnih (JH) segmenata gena teškog lanca sa jednim ili više ljudskih VH, DH, i JHsegmenata gena na endogenom mišjem lokusu imunoglobulina teškog lanca; i b)    endogenom λ (lambda) alelu lakog lanca koji obuhvata nepreraspoređeni ljudski lambda promenljivi (hVλ) i nepreraspoređeni ljudski lambda spojni (hJλ) segment gena, i brisanje prve Vλ-Jλ-Cλ skupine gena pomenutog endogenog mišjeg λ alela lakog lanca i zamenu, u celini ili delimično, Vλ-Jλ segmenata gena druge Vλ-Jλ-Cλ skupine gena pomenutog alela sa pomenutim ljudskim Vλ i Jλ segmentima gena koji su operativno povezani na nedirnuti mišji Cλ konstantni region gena pomenute druge Vλ-Jλ-Jλ skupine gena, pri čemu se endogeni pojačavači Enh 2.4, mišji lambda 3' pojačavač (Enh) i Enh 3.1 održavaju nedirnuti u pomenutom λ alelu lakog lanca.
14.    Mišji embrion obuhvata, napravljen iz, ili koji se može dobiti iz, pomenute mišje ES ćelije prema patentnom zahtevu 13, pri čemu mišji embrion obuhvata: a)    zamenu jednog ili više promenljivih (VH), raznovrsnih (DH) i spojnih (JH) segmenata gena teškog lanca sa jednim ili više ljudskih VH, DH, i JH segmenata gena na endogenom mišjem lokusu imunoglobulina teškog lanca; i b)    endogeni λ (lambda) alel lakog lanca koji obuhvata nepreraspoređeni ljudski lambda promenljivi (hVλ) i nepreraspoređeni ljudski lambda spojni (hJλ) segment gena, i brisanje prve Vλ-Jλ-Cλ skupine gena pomenutog endogenog mišjeg λ alela lakog lanca i zamenu, u celini ili delimično, Vλ-Jλ segmenata gena druge Vλ-Jλ-Cλ skupine gena pomenutog alela sa pomenutim ljudskim Vλ i Jλ segmentima gena koji su operativno povezani na nedirnuti mišji Cλ konstantni region gena pomenute druge Vλ-Jλ-Cλ skupine gena, i pri čemu se endogeni pojačivači Enh 2.4, mišji lambda 3' pojačivač (Enh) i Enh 3.1 održavaju nedirnuti u pomenutomλalelu lakog lanca.
15. Upotreba B ćelije prema patentnom zahtjevu 12 da se napravi hibridom koji ispoljava laki a)    zamenu jednog ili više promenljivih (VH), raznovrsnih (DH) i spojnih (JH) segmenata gena teškog lanca sa jednim ili više ljudskih VH, DH, i JH segmenata gena na endogenom mišjem lokusu imunoglobulina teškog lanca; i b)    endogeni λ (lambda) alel lakog lanca koji obuhvata preraspoređeni ljudski lambda promenljivi (hVλ) i preraspoređeni ljudski lambda spojni (hJλ) segment gena, i brisanje prve Vλ-Jλ- Cλ skupine gena pomenutog endogenog mišjeg λ alela lakog lanca i zamenu, u celini ili delimično, Vλ-Jλ segmenata gena druge Vλ-Jλ-Cλ skupine gena pomenutog alela sa pomenutim ljudskim Vλ i Jλ segmentima gena koji su operativno povezani na nedirnuti mišji Cλ konstantni region gena pomenute druge Vλ-Jλ-Cλ skupine gena i pri čemu endogeni pojačavači Enh 2.4, mišji lambda 3' pojačavač (Enh) i Enh 3.1 održavaju nedirnuti u pomenutom λ alelu lakog lanca.
16.    Hibridom koji ispoljava laki lanac izveden iz hVλ, hJλ i mišjeg Cλ gena pri čemu je hibridom iz, ili se može dobiti iz miša prema bilo kom od patentnih zahteva 1 do 10, pri čemu ćelija obuhvata: a) zamenu jednog ili više promenljivih (VH), raznovrsnih (DH) i spojnih (JH) segmenata gena teškog lanca sa jednim ili više ljudskih VH, DH, i JH segmenata gena na endogenom mišjem lokusu imunoglobulina teškog lanca; i b)    endogeni λ (lambda) alel lakog lanca koji obuhvata preraspoređeni ljudski lambda promenljivi (hVλ) i preraspoređeni ljudski lambda spojni (hJλ) segment gena, i brisanje prve Vλ-Jλ- Cλ skupine gena pomenutog endogenog mišjeg λ alela lakog lanca i zamenu, u celini ili delimično, Vλ-Jλ segmenata gena druge Vλ-Jλ-Cλ skupine gena pomenutog alela sa pomenutim ljudskim Vλ i Jλ segmentima gena koji su operativno povezani na nedirnuti mišji Cλ konstantni region gena pomenute druge Vλ-Jλ-Cλ skupine gena i pri čemu endogeni pojačavači Enh 2.4, mišji lambda 3' pojačavač (Enh) i Enh 3.1 održavaju nedirnuti u pomenutom λ alelu lakog lanca.
17.    Postupak za pravljenje antitela kod miša koji obuhvata: a)    izlaganje miša prema patentnom zahtevu 1 antigenu; b)    omogućavanje mišu da razvije imuni odgovor na antigen; i c)    izolovanje iz miša (b) antitela koje specifično prepoznaje antigen, ili izolovanje iz miša (b) ćelije koja obuhvata domen imunoglobulina koji specifično prepoznaje antigen, ili identifikovanje kod miša (b) sekvence nukleinske kiseline koja kodira promenljivi domen teškog i/ili lakog lanca koji vezuje antigen, pri čemu antitijelo obuhvata laki lanac izveden iz hVλ, hJλ i mišjeg Cλ gena.
MEP-2016-119A 2010-06-22 2011-06-22 Miševi koji ispoljavaju laki lanac hibridnog imunoglobulina sa promenljivim regionom čovjeka ME02442B (me)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US35731410P 2010-06-22 2010-06-22
US35731710P 2010-06-22 2010-06-22
EP12195716.1A EP2568049B1 (en) 2010-06-22 2011-06-22 Mice expressing an immunoglobulin hybrid light chain with a human variable region

Publications (1)

Publication Number Publication Date
ME02442B true ME02442B (me) 2016-09-20

Family

ID=44509861

Family Applications (5)

Application Number Title Priority Date Filing Date
MEP-2016-132A ME02440B (me) 2010-06-22 2011-06-22 Miševi koji ispoljavaju laki lanac sa ljudskim lambda promenljivim regionom i mišjim konstantnim regionom
MEP-2016-87A ME02444B (me) 2010-06-22 2011-06-22 Hibridni laki lanac imunoglobulina koji ispouavaju miševi
MEP-2016-119A ME02442B (me) 2010-06-22 2011-06-22 Miševi koji ispoljavaju laki lanac hibridnog imunoglobulina sa promenljivim regionom čovjeka
MEP-2017-244A ME02902B (me) 2010-06-22 2011-06-22 Transgeni miševi sa modifikovanim lokusom endogenog lambda imunoglobulina
MEP-2019-128A ME03386B (me) 2010-06-22 2011-06-22 Hibridni laki lanac imunoglobulina koji ispoljavaju miševi

Family Applications Before (2)

Application Number Title Priority Date Filing Date
MEP-2016-132A ME02440B (me) 2010-06-22 2011-06-22 Miševi koji ispoljavaju laki lanac sa ljudskim lambda promenljivim regionom i mišjim konstantnim regionom
MEP-2016-87A ME02444B (me) 2010-06-22 2011-06-22 Hibridni laki lanac imunoglobulina koji ispouavaju miševi

Family Applications After (2)

Application Number Title Priority Date Filing Date
MEP-2017-244A ME02902B (me) 2010-06-22 2011-06-22 Transgeni miševi sa modifikovanim lokusom endogenog lambda imunoglobulina
MEP-2019-128A ME03386B (me) 2010-06-22 2011-06-22 Hibridni laki lanac imunoglobulina koji ispoljavaju miševi

Country Status (30)

Country Link
US (22) US9035128B2 (me)
EP (7) EP2568049B1 (me)
JP (17) JP6009441B2 (me)
KR (16) KR101970944B1 (me)
CN (4) CN103068994B (me)
AU (1) AU2011271046B2 (me)
BR (3) BR112012032991B1 (me)
CA (2) CA2804311C (me)
CY (5) CY1117537T1 (me)
DK (5) DK2905338T3 (me)
ES (5) ES2570131T3 (me)
HR (5) HRP20160794T1 (me)
HU (5) HUE029691T2 (me)
IL (12) IL313063A (me)
LT (4) LT3034608T (me)
ME (5) ME02440B (me)
MX (6) MX347322B (me)
MY (6) MY195214A (me)
NO (1) NO2905338T3 (me)
NZ (6) NZ627119A (me)
PL (5) PL2480675T3 (me)
PT (5) PT3034608T (me)
RS (5) RS55037B1 (me)
RU (3) RU2724736C2 (me)
SG (4) SG10201504324UA (me)
SI (5) SI2480675T1 (me)
SM (5) SMT201900241T1 (me)
TR (1) TR201905992T4 (me)
WO (2) WO2011163314A1 (me)
ZA (5) ZA201300062B (me)

Families Citing this family (96)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6596541B2 (en) 2000-10-31 2003-07-22 Regeneron Pharmaceuticals, Inc. Methods of modifying eukaryotic cells
US20050144655A1 (en) 2000-10-31 2005-06-30 Economides Aris N. Methods of modifying eukaryotic cells
WO2010039900A2 (en) 2008-09-30 2010-04-08 Aliva Biopharmaceuticals, Inc. Non-human mammals for the production of chimeric antibodies
CA2747534C (en) 2008-12-18 2020-08-18 Erasmus University Medical Center Rotterdam Non-human transgenic animals expressing humanised antibodies and use therof
US9445581B2 (en) 2012-03-28 2016-09-20 Kymab Limited Animal models and therapeutic molecules
CN102638971B (zh) 2009-07-08 2015-10-07 科马布有限公司 动物模型及治疗分子
HRP20151188T4 (hr) 2010-02-08 2021-10-01 Regeneron Pharmaceuticals, Inc. Miš sa zajedničkim lakim lancem
US20130045492A1 (en) 2010-02-08 2013-02-21 Regeneron Pharmaceuticals, Inc. Methods For Making Fully Human Bispecific Antibodies Using A Common Light Chain
US9796788B2 (en) 2010-02-08 2017-10-24 Regeneron Pharmaceuticals, Inc. Mice expressing a limited immunoglobulin light chain repertoire
PL3251503T3 (pl) 2010-03-31 2024-07-08 Ablexis, Llc Modyfikacja myszy metodami inżynierii genetycznej w celu wytworzenia przeciwciał chimerycznych
SI2480675T1 (sl) 2010-06-22 2016-08-31 Regeneron Pharmaceuticals, Inc. Miši, ki izražajo lahko verigo s spremenljivo regijo humanega lambda in konstantno mišjo regijo
US10793829B2 (en) 2010-07-26 2020-10-06 Trianni, Inc. Transgenic mammals and methods of use thereof
US10662256B2 (en) 2010-07-26 2020-05-26 Trianni, Inc. Transgenic mammals and methods of use thereof
RU2580017C2 (ru) 2010-07-26 2016-04-10 Трианни, Инк. Трансгенные животные и способы применения
KR102306967B1 (ko) 2010-08-02 2021-10-01 리제너론 파아마슈티컬스, 인크. Ｖｌ 도메인을 포함하는 결합 단백질을 생성하는 마우스
PT3865581T (pt) 2011-08-05 2024-10-04 Regeneron Pharma Murganhos da cadeia leve universal humanizada
AU2012311286B2 (en) 2011-09-19 2018-07-26 Kymab Limited Antibodies, variable domains and chains tailored for human use
EP3741862A1 (en) 2011-09-19 2020-11-25 Kymab Limited Animals, repertoires & methods for the production of human antibodies
WO2013045916A1 (en) 2011-09-26 2013-04-04 Kymab Limited Chimaeric surrogate light chains (slc) comprising human vpreb
US9253965B2 (en) 2012-03-28 2016-02-09 Kymab Limited Animal models and therapeutic molecules
PT3527070T (pt) 2011-12-20 2025-12-19 Regeneron Pharma Murganhos de cadeia leve humanizada
US20140013456A1 (en) 2012-03-16 2014-01-09 Regeneron Pharmaceuticals, Inc. Histidine Engineered Light Chain Antibodies and Genetically Modified Non-Human Animals for Generating the Same
HK1200271A1 (en) 2012-03-16 2015-08-07 瑞泽恩制药公司 Mice that produce antigen-binding proteins with ph-dependent binding characteristics
KR102213535B1 (ko) 2012-03-16 2021-02-08 리제너론 파마슈티칼스 인코포레이티드 pH-민감성 면역글로불린 서열을 발현하는 비-사람 동물
DK2825036T3 (en) 2012-03-16 2018-07-16 Regeneron Pharma Histidine engineered light chain antibodies and genetically modified rodents to generate them
EP2831245A1 (en) 2012-03-28 2015-02-04 Kymab Limited Transgenic non-human vertebrate for the expression of class - switched, fully human, antibodies
US10251377B2 (en) 2012-03-28 2019-04-09 Kymab Limited Transgenic non-human vertebrate for the expression of class-switched, fully human, antibodies
GB2502127A (en) * 2012-05-17 2013-11-20 Kymab Ltd Multivalent antibodies and in vivo methods for their production
MY185881A (en) 2013-02-20 2021-06-14 Regeneron Pharma Non-human animals with modified immunoglobulin heavy chain sequences
EP4218409B1 (en) * 2013-03-13 2025-02-12 Regeneron Pharmaceuticals, Inc. Mice expressing a limited immunoglobulin light chain repertoire
PL2967012T3 (pl) 2013-03-14 2021-04-19 Erasmus University Medical Center Rotterdam Transgeniczne ssaki inne niż człowiek do wytwarzania przeciwciał
US9788534B2 (en) 2013-03-18 2017-10-17 Kymab Limited Animal models and therapeutic molecules
US9783618B2 (en) 2013-05-01 2017-10-10 Kymab Limited Manipulation of immunoglobulin gene diversity and multi-antibody therapeutics
US11707056B2 (en) 2013-05-02 2023-07-25 Kymab Limited Animals, repertoires and methods
US9783593B2 (en) 2013-05-02 2017-10-10 Kymab Limited Antibodies, variable domains and chains tailored for human use
JP6621750B2 (ja) * 2013-09-18 2019-12-18 リジェネロン・ファーマシューティカルズ・インコーポレイテッドＲｅｇｅｎｅｒｏｎ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． ヒスチジン操作軽鎖抗体およびそれを生成するための遺伝子改変非ヒト動物
CA2925723A1 (en) 2013-10-01 2015-04-09 Kymab Limited Animal models and therapeutic molecules
US20170101460A1 (en) * 2014-01-10 2017-04-13 Allermabs Co. Ltd. Transgenic animals capable of producing humanized ige at much higher levels than mouse ige
CN106164092A (zh) * 2014-03-21 2016-11-23 瑞泽恩制药公司 表现不同结合特征的vl抗原结合蛋白
CN106255410B (zh) 2014-03-21 2020-01-10 瑞泽恩制药公司 产生单结构域结合蛋白的非人动物
AU2015271709B2 (en) 2014-06-06 2020-11-26 Bristol-Myers Squibb Company Antibodies against glucocorticoid-induced tumor necrosis factor receptor (GITR) and uses thereof
KR20170083534A (ko) 2014-09-19 2017-07-18 리제너론 파마슈티칼스 인코포레이티드 키메라 항원 수용체
SG10201902924RA (en) 2014-10-03 2019-05-30 Massachusetts Inst Technology Antibodies that bind ebola glycoprotein and uses thereof
TWI711630B (zh) 2014-11-21 2020-12-01 美商必治妥美雅史谷比公司 抗ｃｄ７３抗體及其用途
CN107278206B (zh) 2014-12-19 2021-04-02 雷根尼桑斯公司 结合人c6的抗体及其用途
MY187045A (en) 2014-12-23 2021-08-27 Bristol Myers Squibb Co Antibodies to tigit
WO2016124709A1 (de) 2015-02-05 2016-08-11 Basf Se Solarkraftwerk mit einem ersten wärmeträgerkreislauf und einem zweiten wärmeträgerkreislauf
US11111314B2 (en) 2015-03-19 2021-09-07 Regeneron Pharmaceuticals, Inc. Non-human animals that select for light chain variable regions that bind antigen
EA035412B1 (ru) 2015-05-29 2020-06-10 Бристол-Майерс Сквибб Компани Антитела к ox40 и их применение
US10479838B2 (en) 2015-06-29 2019-11-19 Bristol-Myers Squibb Company Antibodies to CD40 with enhanced agonist activity
CN105274116B (zh) * 2015-10-21 2020-09-29 重庆金迈博生物科技有限公司 一种制备人源化抗体的核酸分子及其应用
CA3005855A1 (en) 2015-11-19 2017-05-26 Bristol-Myers Squibb Company Antibodies against glucocorticoid-induced tumor necrosis factor receptor (gitr) and uses thereof
WO2017095939A1 (en) 2015-12-03 2017-06-08 Trianni, Inc. Enhanced immunoglobulin diversity
AU2017213633B2 (en) 2016-02-04 2023-08-03 Trianni, Inc. Enhanced production of immunoglobulins
CA3016187A1 (en) 2016-03-04 2017-09-08 Bristol-Myers Squibb Company Combination therapy with anti-cd73 antibodies
KR20180114223A (ko) 2016-03-04 2018-10-17 더 락커펠러 유니버시티 증진된 효능제 활성을 갖는 cd40에 대한 항체
US10968279B2 (en) 2016-05-09 2021-04-06 Bristol-Myers Squibb Company TL1A antibodies and uses thereof
US20170332610A1 (en) 2016-05-20 2017-11-23 Regeneron Pharmaceuticals, Inc. Methods for breaking immunological tolerance using multiple guide rnas
KR102483193B1 (ko) 2016-06-03 2023-01-04 리제너론 파마슈티칼스 인코포레이티드 외인성 말단 데옥시뉴클레오타이드 전달효소를 발현하는 비인간 동물
WO2017214089A1 (en) 2016-06-06 2017-12-14 Regeneron Pharmaceuticals, Inc. Non-human animals expressing antibodies with human lambda light chains
US20170371963A1 (en) * 2016-06-27 2017-12-28 Facebook, Inc. Systems and methods for identifying matching content
SG11201900026TA (en) 2016-07-14 2019-01-30 Bristol Myers Squibb Co Antibodies against tim3 and uses thereof
US10981976B2 (en) 2016-08-31 2021-04-20 University Of Rochester Human monoclonal antibodies to human endogenous retrovirus K envelope (HERV-K) and use thereof
CA3040189A1 (en) 2016-10-13 2018-04-19 Massachusetts Institute Of Technology Antibodies that bind zika virus envelope protein and uses thereof
CN109906272A (zh) 2016-10-31 2019-06-18 国立大学法人鸟取大学 产生人抗体的非人动物和使用该非人动物的人抗体制作方法
PT4082334T (pt) 2016-11-04 2025-05-21 Regeneron Pharma Animais não humanos possuindo um lócus da cadeia leve lambda de immunoglobulina geneticamente modificada
EA201991720A1 (ru) 2017-02-17 2020-01-20 Бристол-Маерс Сквибб Компани Антитела к альфа-синуклеину и их применения
TWI788340B (zh) 2017-04-07 2023-01-01 美商必治妥美雅史谷比公司 抗icos促效劑抗體及其用途
TW202438676A (zh) 2017-12-05 2024-10-01 美商再生元醫藥公司 具有經改造免疫球蛋白λ輕鏈的非人類動物及其用途
JP7358361B2 (ja) 2018-01-12 2023-10-10 ブリストル－マイヤーズ スクイブ カンパニー Ｔｉｍ３に対する抗体およびその使用
CA3093407A1 (en) 2018-03-23 2019-09-26 Bristol-Myers Squibb Company Antibodies against mica and/or micb and uses thereof
SG11202008799PA (en) 2018-03-24 2020-10-29 Regeneron Pharma Genetically modified non-human animals for generating therapeutic antibodies against peptide-mhc complexes, methods of making and uses thereof
WO2019190990A1 (en) 2018-03-26 2019-10-03 Regeneron Pharmaceuticals, Inc. Humanized rodents for testing therapeutic agents
WO2019236671A1 (en) * 2018-06-08 2019-12-12 Crystal Bioscience Inc. Transgenic animal for producing diversified antibodies that have the same light chain ii
IL318469A (en) 2018-06-14 2025-03-01 Regeneron Pharma Non-human animals capable of reorganizing transgenic DH-DH, and their uses
US20220003822A1 (en) 2018-10-26 2022-01-06 Vehicle Energy Japan Inc. Battery control device
BR112021009111A2 (pt) 2018-11-16 2021-08-24 Bristol-Myers Squibb Company Anticorpos anti-nkg2a e usos dos mesmos
EP3914622A1 (en) 2019-01-22 2021-12-01 Bristol-Myers Squibb Company Antibodies against il-7r alpha subunit and uses thereof
SG11202107589PA (en) 2019-02-22 2021-08-30 Regeneron Pharma Rodents having genetically modified sodium channels and methods of use thereof
SG11202111258TA (en) * 2019-06-05 2021-11-29 Regeneron Pharma Non-human animals having a limited lambda light chain repertoire expressed from the kappa locus and uses thereof
FI3993623T3 (fi) * 2019-07-01 2025-05-25 Zoetis Services Llc Muuntogeeniset jyrsijät ja niiden käyttömenetelmät
IL293330A (en) 2019-12-02 2022-07-01 Regeneron Pharma mhc ii peptide protein structures and uses thereof
WO2021231732A1 (en) 2020-05-15 2021-11-18 Bristol-Myers Squibb Company Antibodies to garp
WO2021261620A1 (ko) * 2020-06-25 2021-12-30 주식회사 휴맵 이형접합성 형질전환 동물
KR20230066386A (ko) 2020-09-11 2023-05-15 리제너론 파마슈티칼스 인코포레이티드 항원 특이적 항체의 확인 및 제조
AU2021400584A1 (en) 2020-12-16 2023-06-29 Regeneron Pharmaceuticals, Inc. Mice expressing humanized fc alpha receptors
KR20230124594A (ko) 2020-12-23 2023-08-25 리제너론 파마슈티칼스 인코포레이티드 막관통 단백질 및 이를 생산하는 세포에 결합하는 항체를 수득하는 방법
US20240317849A1 (en) 2020-12-23 2024-09-26 Regeneron Pharmaceuticals, Inc. Nucleic acids encoding anchor modified antibodies and uses thereof
WO2023199655A1 (ja) 2022-04-13 2023-10-19 日本精工株式会社 軸受装置の状態の検出方法、検出装置、およびプログラム
USD999969S1 (en) * 2022-04-29 2023-09-26 Shenzhen Intellirocks Tech. Co., Ltd. Lamp
WO2024163477A1 (en) 2023-01-31 2024-08-08 University Of Rochester Immune checkpoint blockade therapy for treating staphylococcus aureus infections
EP4705342A2 (en) 2023-05-04 2026-03-11 Novasenta, Inc. Anti-cd161 antibodies and methods of use thereof
US20250361320A1 (en) 2024-02-27 2025-11-27 Bristol-Myers Squibb Company Anti-ceacam5 antibodies and uses thereof
WO2026030428A2 (en) 2024-08-01 2026-02-05 Regeneron Pharmaceuticals, Inc. Prostate-specific antigen peptides and uses thereof
US20260123608A1 (en) 2024-08-06 2026-05-07 Regeneron Pharmaceuticals, Inc. Non-human animals having modified immunoglobulin heavy chain constant region locus and uses thereof
WO2026096736A1 (en) 2024-10-31 2026-05-07 Regeneron Pharmaceuticals, Inc. Rodents expressing humanized polymeric immunoglobulin receptor

Family Cites Families (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8823869D0 (en) * 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
US6673986B1 (en) 1990-01-12 2004-01-06 Abgenix, Inc. Generation of xenogeneic antibodies
US5770429A (en) * 1990-08-29 1998-06-23 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US7041871B1 (en) * 1995-10-10 2006-05-09 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
AU662148B2 (en) 1991-04-10 1995-08-24 Scripps Research Institute, The Heterodimeric receptor libraries using phagemids
CA2078539C (en) 1991-09-18 2005-08-02 Kenya Shitara Process for producing humanized chimera antibody
US6632976B1 (en) 1995-08-29 2003-10-14 Kirin Beer Kabushiki Kaisha Chimeric mice that are produced by microcell mediated chromosome transfer and that retain a human antibody gene
ATE549918T1 (de) * 1996-12-03 2012-04-15 Amgen Fremont Inc Menschliche antikörper, die ausdrücklich menschliches tnf alpha binden
US6774279B2 (en) 1997-05-30 2004-08-10 Carnegie Institution Of Washington Use of FLP recombinase in mice
GB9823930D0 (en) 1998-11-03 1998-12-30 Babraham Inst Murine expression of human ig\ locus
CN101498731A (zh) * 2000-05-18 2009-08-05 日本烟草产业株式会社 抗协同刺激信号转导分子ailim的人单克隆抗体及其药物用途
US6586251B2 (en) 2000-10-31 2003-07-01 Regeneron Pharmaceuticals, Inc. Methods of modifying eukaryotic cells
US6596541B2 (en) 2000-10-31 2003-07-22 Regeneron Pharmaceuticals, Inc. Methods of modifying eukaryotic cells
IL155977A0 (en) * 2000-11-30 2003-12-23 Medarex Inc Transgenic transchromosomal rodents for making human antibodies
GB0031284D0 (en) * 2000-12-21 2001-01-31 Ks Biomedix Ltd High affinity antibodies
EP1970448A1 (en) * 2001-05-11 2008-09-17 Kirin Pharma Kabushiki Kaisha Human artificial chromosome containting human antibody lambda light chain and non-human animal containting the human artificial chromosome capable of genetic transmission
GB0115256D0 (en) * 2001-06-21 2001-08-15 Babraham Inst Mouse light chain locus
EP3698626A1 (en) 2001-11-30 2020-08-26 Amgen Fremont Inc. Transgenic animals bearing human ig lambda light chain genes
US20030217171A1 (en) 2002-05-17 2003-11-20 Von Stuermer Wolfgang R. Self-replicating and self-installing software apparatus
CN103205436B (zh) * 2003-07-15 2016-05-25 人类多克隆治疗公司 人源化免疫球蛋白基因座
CN1605628A (zh) * 2003-09-03 2005-04-13 中国疾病预防控制中心病毒病预防控制所 Cho细胞生产的人源抗甲肝病毒基因工程抗体
PT1773885E (pt) * 2004-08-05 2010-07-21 Genentech Inc Antagonistas anti-cmet humanizados
WO2006044962A1 (en) 2004-10-19 2006-04-27 Regeneron Pharmaceuticals, Inc. Method for generating an animal homozygous for a genetic modification
CN101111521B (zh) * 2004-12-29 2011-08-24 株式会社柳韩洋行 肿瘤坏死因子-α特异性人源化抗体
JP5514539B2 (ja) 2006-03-31 2014-06-04 メダレックス・リミテッド・ライアビリティ・カンパニー ヒト抗体の調製に用いるためのキメラ抗体を発現するトランスジェニック動物
WO2008022391A1 (en) * 2006-08-22 2008-02-28 G2 Inflammation Pty Ltd Method for producing antibodies
LT2769992T (lt) 2006-10-02 2021-04-12 Regeneron Pharmaceuticals, Inc. Didelio afiniškumo žmogaus antikūnai, atpažįstantys žmogaus il-4 receptorių
US7864492B2 (en) 2006-10-31 2011-01-04 Siemens Industry, Inc. Systems and methods for arc fault detection
DE102007045897A1 (de) 2007-09-26 2009-04-09 Carl Zeiss Microimaging Gmbh Verfahren zur mikroskopischen dreidimensionalen Abbildung einer Probe
EP2271758B1 (en) * 2008-04-14 2018-09-12 Innovative Targeting Solutions Inc. Sequence diversity generation in immunoglobulins
ES2436044T3 (es) * 2008-05-23 2013-12-26 Ablexis, Llc Procedimiento de generación de anticuerpos de dominio VL individual en animales transgénicos
WO2010039900A2 (en) 2008-09-30 2010-04-08 Aliva Biopharmaceuticals, Inc. Non-human mammals for the production of chimeric antibodies
CA2747534C (en) * 2008-12-18 2020-08-18 Erasmus University Medical Center Rotterdam Non-human transgenic animals expressing humanised antibodies and use therof
CN102638971B (zh) * 2009-07-08 2015-10-07 科马布有限公司 动物模型及治疗分子
HRP20151188T4 (hr) * 2010-02-08 2021-10-01 Regeneron Pharmaceuticals, Inc. Miš sa zajedničkim lakim lancem
CN103228130B (zh) 2010-06-17 2016-03-16 科马布有限公司 动物模型及治疗分子
SI2480675T1 (sl) 2010-06-22 2016-08-31 Regeneron Pharmaceuticals, Inc. Miši, ki izražajo lahko verigo s spremenljivo regijo humanega lambda in konstantno mišjo regijo

Also Published As

Publication number Publication date
NZ626979A (en) 2015-05-29
CN103068994B (zh) 2016-01-20
AU2011271043A8 (en) 2016-01-21
CA2804311A1 (en) 2011-12-29
PL3034608T3 (pl) 2019-08-30
KR20180135996A (ko) 2018-12-21
NZ605758A (en) 2014-08-29
US20200239837A1 (en) 2020-07-30
RU2016119423A3 (me) 2019-11-19
MY194456A (en) 2022-11-30
AU2011271043A9 (en) 2015-10-01
PT2480676E (pt) 2016-06-09
SI2905338T1 (sl) 2017-12-29
US9226484B2 (en) 2016-01-05
JP6963542B2 (ja) 2021-11-10
HRP20160794T1 (hr) 2016-08-12
IL291301A (en) 2022-05-01
EP2480675A1 (en) 2012-08-01
ME02902B (me) 2018-04-20
US9150662B2 (en) 2015-10-06
US20190153384A1 (en) 2019-05-23
MX347318B (es) 2017-04-21
US20150246977A1 (en) 2015-09-03
KR20180135997A (ko) 2018-12-21
US20140137275A1 (en) 2014-05-15
IL264634B (en) 2019-09-26
JP6243384B2 (ja) 2017-12-06
US20240327785A1 (en) 2024-10-03
DK3034608T3 (da) 2019-05-06
CY1118126T1 (el) 2017-06-28
US20150089680A1 (en) 2015-03-26
US9006511B2 (en) 2015-04-14
MY157477A (en) 2016-06-15
KR20190014576A (ko) 2019-02-12
RU2016119423A (ru) 2018-11-07
US20170258059A1 (en) 2017-09-14
LT2480675T (lt) 2016-10-10
KR20210134424A (ko) 2021-11-09
ZA201300063B (en) 2014-09-25
IL300712B1 (en) 2024-07-01
CN104342455B (zh) 2017-05-31
CY1119478T1 (el) 2018-03-07
US20130323790A1 (en) 2013-12-05
CA2804311C (en) 2017-09-12
IL282872A (en) 2021-06-30
PL2905338T3 (pl) 2018-01-31
SG186390A1 (en) 2013-01-30
RU2724736C2 (ru) 2020-06-25
HK1183321A1 (en) 2013-12-20
US20120073004A1 (en) 2012-03-22
JP6341972B2 (ja) 2018-06-13
NO2905338T3 (me) 2017-12-30
EP2905338B8 (en) 2018-01-24
JP2018201528A (ja) 2018-12-27
JP5988969B2 (ja) 2016-09-07
EP2905338A1 (en) 2015-08-12
IL259965B (en) 2019-02-28
US20150173331A1 (en) 2015-06-25
JP2017006152A (ja) 2017-01-12
MY195217A (en) 2023-01-11
US9035128B2 (en) 2015-05-19
SMT201600213B (it) 2016-08-31
PT3034608T (pt) 2019-05-28
SMT201600229B (me) 2016-08-31
WO2011163314A1 (en) 2011-12-29
ES2646052T3 (es) 2017-12-11
KR20130027555A (ko) 2013-03-15
JP2026066390A (ja) 2026-04-16
ME03386B (me) 2020-01-20
US9394373B2 (en) 2016-07-19
HUE036597T2 (hu) 2018-07-30
JP6545773B2 (ja) 2019-07-17
US20170107484A1 (en) 2017-04-20
US20160057979A1 (en) 2016-03-03
IL269078B (en) 2021-05-31
IL282872B (en) 2022-04-01
JP2018201527A (ja) 2018-12-27
SMT201600212B (it) 2016-08-31
KR102506001B1 (ko) 2023-03-07
LT2905338T (lt) 2017-12-27
US20130326647A1 (en) 2013-12-05
CN104342455A (zh) 2015-02-11
SMT201900241T1 (it) 2019-05-10
CA2803864A1 (en) 2011-12-29
ES2570131T3 (es) 2016-05-17
JP2016010415A (ja) 2016-01-21
AU2011271046B2 (en) 2015-10-01
DK2568049T3 (en) 2016-08-01
US9163092B2 (en) 2015-10-20
ME02444B (me) 2016-09-20
DK2905338T3 (da) 2017-11-06
ME02440B (me) 2016-09-20
CN104404050B (zh) 2018-06-08
CY1122877T1 (el) 2021-05-05
HRP20160865T1 (hr) 2016-10-07
ZA201300062B (en) 2014-09-25
HRP20190807T1 (hr) 2019-08-23
IL223719A (en) 2016-10-31
US9066502B2 (en) 2015-06-30
KR102118565B1 (ko) 2020-06-03
RU2013102596A (ru) 2014-07-27
RS55042B1 (sr) 2016-12-30
US20160060359A1 (en) 2016-03-03
KR20200064166A (ko) 2020-06-05
US9012717B2 (en) 2015-04-21
JP2018023403A (ja) 2018-02-15
IL259965A (en) 2018-07-31
MX2012015298A (es) 2013-05-01
US9206263B2 (en) 2015-12-08
EP3205726A1 (en) 2017-08-16
ZA201404601B (en) 2016-02-24
ZA201404600B (en) 2015-09-30
RS54891B1 (sr) 2016-10-31
DK2480675T3 (en) 2016-08-01
KR20200143511A (ko) 2020-12-23
US9206262B2 (en) 2015-12-08
IL223720A (en) 2017-05-29
PL2568049T3 (pl) 2017-03-31
BR122020013427B1 (pt) 2021-08-03
PL2480676T3 (pl) 2016-10-31
KR101991234B1 (ko) 2019-06-20
IL291301B2 (en) 2023-07-01
CA2803864C (en) 2017-05-16
KR101975884B1 (ko) 2019-05-10
LT3034608T (lt) 2019-05-27
SG10201504568YA (en) 2015-07-30
KR20190049932A (ko) 2019-05-09
JP2013531501A (ja) 2013-08-08
NZ707200A (en) 2016-04-29
KR20210013376A (ko) 2021-02-03
KR102211911B1 (ko) 2021-02-05
IL247386A (en) 2017-07-31
KR102059909B1 (ko) 2019-12-27
US10266803B2 (en) 2019-04-23
US20180064078A1 (en) 2018-03-08
HK1170766A1 (zh) 2013-03-08
TR201905992T4 (tr) 2019-05-21
KR102320944B1 (ko) 2021-11-04
KR102193823B1 (ko) 2020-12-22
SI2480675T1 (sl) 2016-08-31
MX336344B (es) 2016-01-15
PT2480675T (pt) 2016-07-11
EP2480676B1 (en) 2016-04-06
HK1226766A1 (en) 2017-10-06
IL255179B (en) 2018-06-28
US9334333B2 (en) 2016-05-10
JP6009441B2 (ja) 2016-10-19
US20150246976A1 (en) 2015-09-03
JP2021061863A (ja) 2021-04-22
KR20190014578A (ko) 2019-02-12
BR112012032991A2 (pt) 2015-10-06
IL300712B2 (en) 2024-11-01
CN103068994A (zh) 2013-04-24
JP2019033765A (ja) 2019-03-07
IL255179A0 (en) 2017-12-31
KR101934852B1 (ko) 2019-01-04
RS55037B1 (sr) 2016-12-30
KR20130121814A (ko) 2013-11-06
LT2568049T (lt) 2016-10-10
MX347322B (es) 2017-04-21
BR112012032991A8 (pt) 2020-09-29
EP3034608B1 (en) 2019-01-30
JP2020062061A (ja) 2020-04-23
BR112012033248A2 (pt) 2017-11-28
PL2480675T3 (pl) 2017-03-31
PT2568049T (pt) 2016-07-11
US20150176002A1 (en) 2015-06-25
US9850462B2 (en) 2017-12-26
JP2017012204A (ja) 2017-01-19
US20120070861A1 (en) 2012-03-22
JP2020128440A (ja) 2020-08-27
JP2023133554A (ja) 2023-09-22
CN103068993B (zh) 2016-01-06
BR112012032991B1 (pt) 2021-08-10
KR20190142436A (ko) 2019-12-26
RU2013102595A (ru) 2014-07-27
JP2013532974A (ja) 2013-08-22
JP2022066449A (ja) 2022-04-28
ZA201506598B (en) 2017-03-29
CN103068993A (zh) 2013-04-24
US20150320023A1 (en) 2015-11-12
RS58736B1 (sr) 2019-06-28
HRP20160497T1 (hr) 2016-07-15
HUE029692T2 (en) 2017-03-28
AU2011271043A1 (en) 2013-01-31
EP3034608A1 (en) 2016-06-22
JP7236409B2 (ja) 2023-03-09
IL300712A (en) 2023-04-01
MY195214A (en) 2023-01-11
KR102462042B1 (ko) 2022-11-03
KR102001430B1 (ko) 2019-07-18
KR20210073609A (ko) 2021-06-18
CY1117537T1 (el) 2017-04-26
ES2575223T3 (es) 2016-06-27
KR101945352B1 (ko) 2019-02-07
NZ627119A (en) 2015-05-29
KR102266097B1 (ko) 2021-06-18
PT2905338T (pt) 2017-11-10
RS56589B1 (sr) 2018-02-28
NZ605751A (en) 2014-10-31
IL269078A (en) 2019-11-28
JP6073441B2 (ja) 2017-02-01
HUE044001T2 (hu) 2019-09-30
AU2011271046A1 (en) 2013-01-31
CN104404050A (zh) 2015-03-11
SI3034608T1 (sl) 2019-06-28
US9206261B2 (en) 2015-12-08
JP2025027148A (ja) 2025-02-26
IL291301B1 (en) 2023-03-01
WO2011163311A1 (en) 2011-12-29
US9029628B2 (en) 2015-05-12
AU2011271043B2 (en) 2015-10-01
US9399683B2 (en) 2016-07-26
SG186391A1 (en) 2013-01-30
SI2480676T1 (sl) 2016-10-28
MX348942B (es) 2017-07-04
MX2012015300A (es) 2013-05-01
US20150351371A1 (en) 2015-12-10
CY1117692T1 (el) 2017-05-17
KR101970944B1 (ko) 2019-04-23
US9844212B2 (en) 2017-12-19
EP2568049A1 (en) 2013-03-13
US20150173332A1 (en) 2015-06-25
KR20190073584A (ko) 2019-06-26
IL244450A0 (en) 2016-04-21
MY165287A (en) 2018-03-21
EP2568049B1 (en) 2016-04-13
MX2022002117A (es) 2022-03-17
KR20220150430A (ko) 2022-11-10
US9540452B2 (en) 2017-01-10
EP2480675B1 (en) 2016-04-06
SG10201504324UA (en) 2015-07-30
RU2590594C2 (ru) 2016-07-10
ES2576928T3 (es) 2016-07-12
HUE029691T2 (en) 2017-03-28
ES2721749T3 (es) 2019-08-05
HK1168384A1 (zh) 2012-12-28
RU2601297C2 (ru) 2016-10-27
NZ707198A (en) 2016-04-29
HUE030285T2 (en) 2017-05-29
SI2568049T1 (sl) 2016-10-28
IL313063A (en) 2024-07-01
EP2480676A1 (en) 2012-08-01
SMT201700506T1 (it) 2018-01-11
HRP20171666T1 (hr) 2017-12-15
JP2016010417A (ja) 2016-01-21
IL244450A (en) 2017-11-30
EP3456832A1 (en) 2019-03-20
EP2905338B1 (en) 2017-08-02
US20190203171A1 (en) 2019-07-04
KR20230036157A (ko) 2023-03-14
MY195212A (en) 2023-01-11
DK2480676T3 (en) 2016-06-20

Similar Documents

Publication Publication Date Title
HRP20171357T1 (hr) Ograničeni teški lanac imunoglobulina u miševa
HRP20230490T1 (hr) Miševi koji izražavaju ograničeni repertoar lakog lanca imunoglobulina
HRP20190807T1 (hr) Miševi koji izražavaju imunoglobulinski hibridni laki lanac s humanom varijabilnom regijom
JP2015502177A5 (me)
Jaffe et al. Functional antibodies exhibit light chain coherence
HRP20250695T1 (hr) Ne-ljudske životinje koje imaju konstruirani lokus imunoglobulinskog lambda lakog lanca
HRP20211126T1 (hr) Humanizirane nehumane životinje s ograničenim lokusima imunoglobulinskog teškog lanca
HRP20231356T1 (hr) Polinukleotidi koji kodiraju protutijela glodavaca s ljudskim idiotipovima i životinje koje ih sadrže
RU2012128856A (ru) Мыши, которые производят антитела, имеющие только тяжелую цепь
JP2014529998A5 (me)
JP2013532974A5 (me)
Moran Mouse platforms jostle for slice of humanized antibody market
HRP20241480T1 (hr) Humanizirani miševi univerzalnog lakog lanca
HRP20161551T4 (hr) Miš sa zajedničkim lakim lancem
Krah et al. Engineering IgG-like bispecific antibodies—an overview
JP2014531452A5 (me)
NZ701825A (en) Heterodimeric antibody fc-containing proteins and methods for production thereof
Mahajan et al. Epitope specific antibodies and T cell receptors in the immune epitope database
JP2015510767A5 (me)
JP2019083823A5 (me)
HRP20192311T1 (hr) Adam6 miševi
ME02817B (me) Generisanje vezujućih molekula
JP2012532598A5 (me)
JP2015509380A5 (me)
RU2014133653A (ru) Гуманизированные грызуны, которые экспрессируют тяжелые цепи, содержащие домены vl